Sai Life Sciences Limited has completed the allotment of 11,100 fully paid-up equity shares under its Employees Stock Option Plan 2008 (ESOP 2008) scheme. The Board of Directors approved this allotment through a circular resolution dated 24 March 2026, as part of the company's employee incentive program.

Share Allotment Details

The allotment represents the exercise of stock options by employees under the ESOP 2008 scheme. The shares were issued at an exercise price of Rs. 188.90 per share, with a premium of Rs. 187.90 per share over the par value of Re. 1.

Share Capital Impact

Following this allotment, the company's share capital structure has been updated. The shares were issued in dematerialized form under ISIN INE570L01029, with distinctive numbers ranging from 211768135 to 211779234.

ESOP 2008 Scheme Overview

The Employees Stock Option Plan 2008 is designed to attract, retain, and reward employees while contributing to the company's growth. The scheme features:

• Maximum vesting period of 5 years with multiple vesting options
• Exercise period extending until the employee remains in service
• Pricing determined by the Nomination and Remuneration Committee in compliance with applicable accounting standards and SEBI regulations

Regulatory Compliance

The allotment was conducted in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company has filed the necessary disclosures with both BSE Limited and National Stock Exchange of India Limited, where its shares are listed.

The shares issued are identical to existing equity shares in all respects, with no lock-in restrictions applicable. This allotment demonstrates the company's commitment to employee participation in its growth through equity-based compensation programs.

Sai Life Sciences Limited has informed stock exchanges about receiving an income tax order related to non-deduction of Tax Deducted at Source (TDS) on payments made to non-residents. The pharmaceutical company disclosed this development under Regulation 30 of SEBI Listing Regulations on 21st March, 2026.

Income Tax Order Details

The Deputy Commissioner of Income Tax (International Taxation) Hyderabad passed an order dated 18th March, 2026, under Section 201(1) of the Income Tax Act, 1961. The company received this order on 20th March, 2026, at 12:16 PM. The order addresses alleged violations concerning non-deduction of TDS on payments made to non-residents for assessment year 2020-21.

Financial Implications

The income tax order specifies significant financial demands against the company:

The total quantified demand amounts to INR 4,53,57,182, with additional penalties that may be assessed separately by the income tax officer.

Company's Response and Strategy

Sai Life Sciences has outlined its approach to address this income tax order. The company plans to file an appeal against the order and expressed confidence in achieving a favorable outcome at the appellate level. Based on the company's assessment, it does not reasonably expect the order to have any material financial impact on its operations.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Circular on Industry Standards Note dated 25th February, 2025. The company provided comprehensive details as required under Schedule III of the Listing Regulations, ensuring transparency with stakeholders regarding this regulatory development.

Assessment Year Context

The income tax order specifically relates to assessment year 2020-21, indicating that the alleged TDS non-deduction issues pertain to transactions conducted during that financial period. The order focuses on payments made to non-resident entities, which typically require TDS deduction under Indian income tax provisions for international transactions.